Alzheimer disease, from molecular biology to therapy.

Part 1 Pathological basis of therapy in Alzheimer's disease: criteria for diagnosis of Alzheimer's disease neuropathology of Alzheimer's disease cell death - excitotoxins, apoptosis and hypometabolism. Part 2 The cholinergic system in brain: treatment of Alzheimer disease cholinesterase inhibitors in Alzheimer disease treatment. Part 3 Nicotinic and muscarnic cholinergic agonists: nicotinic agonists the potential for anti-inflammatory therapy. Part 4 Development of new therapies in Alzheimer's disease: design of clinical trials SPECT and PET. Part 5 Social issues in Alzheimer's disease: legal and ethical issues socio-economic aspects of Alzheimer disease treatment.

[1]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[2]  M. Roth,et al.  The Association Between Quantitative Measures of Dementia and of Senile Change in the Cerebral Grey Matter of Elderly Subjects , 1968, British Journal of Psychiatry.

[3]  P. Greengard,et al.  Protein phosphorylation inhibits production of Alzheimer amyloid beta/A4 peptide. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[4]  C. Gottfries,et al.  Membrane Lipids, Selectively Diminished in Alzheimer Brains, Suggest Synapse Loss as a Primary Event in Early‐Onset Form (Type I) and Demyelination in Late‐Onset Form (Type II) , 1994, Journal of neurochemistry.

[5]  J. Lindstrom,et al.  Neuronal nicotinic acetylcholine receptors. , 1996, Ion channels.

[6]  Andreas Weidemann,et al.  Identification, biogenesis, and localization of precursors of Alzheimer's disease A4 amyloid protein , 1989, Cell.

[7]  Carl W. Cotman,et al.  Neurodegeneration induced by beta-amyloid peptides in vitro: the role of peptide assembly state , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[8]  C. Behl,et al.  The expression of amyloid beta protein precursor protects nerve cells from β-amyloid and glutamate toxicity and alters their interaction with the extracellular matrix , 1993, Brain Research.

[9]  C. Carter,et al.  Presynaptic alpha-2 adrenoceptors play a major role in the effects of idazoxan on cortical noradrenaline release (as measured by in vivo dialysis) in the rat. , 1987, The Journal of pharmacology and experimental therapeutics.

[10]  T. Oltersdorf,et al.  Secreted form of amyloid β protein precursor is involved in the growth regulation of fibroblasts , 1989, Cell.

[11]  F. Checler.  Processing of the β‐Amyloid Precursor Protein and Its Regulation in Alzheimer's Disease , 1995 .

[12]  D. Naritoku,et al.  Effects of nicotine on levels of acetylcholine and biogenic amines in rat cortex , 1994 .

[13]  K. Grzeschik,et al.  The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor , 1987, Nature.

[14]  H. E. Rosvold,et al.  Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. , 1979, Science.

[15]  The regulation of amyloid β protein precursor secretion and its modulatory role in cell adhesion , 1989, Neuron.

[16]  E. Giacobini,et al.  The cholinergic receptor system of the human brain: neurochemical and pharmacological aspects in aging and Alzheimer. , 1989, Progress in brain research.

[17]  C. Gottfries,et al.  The Clinical Efficacy of Citalopram in Treatment of Emotional Disturbances in Dementia Disorders a Nordic Multicentre Study , 1990, British Journal of Psychiatry.

[18]  J. Moreau,et al.  Involvement of amyloid precursor protein in memory formation in the rat: an indirect antibody approach , 1993, Brain Research.

[19]  A. Hofman,et al.  Relation between nicotine intake and Alzheimer's disease. , 1991, BMJ.

[20]  H. Soininen,et al.  Volumetric MRI analysis of the amygdala and the hippocampus in subjects with age‐associated memory impairment , 1994, Neurology.

[21]  F. Gage,et al.  Cholinergic septal grafts into the hippocampal formation improve spatial learning and memory in aged rats by an atropine-sensitive mechanism , 1986, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[22]  J. Growdon,et al.  Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. , 1992, Science.

[23]  K. Davis,et al.  Pharmacological Alleviation of Combined Cholinergic/Noradrenergic Lesion‐Induced Memory Deficits in Rats , 1991, Clinical neuropharmacology.

[24]  M. Mattson,et al.  Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the β-amyloid precursor protein , 1993, Neuron.

[25]  B. Sahakian,et al.  The Effects of Nicotine on Attention, Information Processing, and Short-Term Memory in Patients with Dementia of the Alzheimer Type , 1989, British Journal of Psychiatry.

[26]  M. Bencherif,et al.  RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. , 1996, The Journal of pharmacology and experimental therapeutics.

[27]  P. Greengard,et al.  Cholinergic agonists and interleukin 1 regulate processing and secretion of the Alzheimer beta/A4 amyloid protein precursor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[28]  E. Giacobini,et al.  Quantitative Determination of Acetylcholinesterase Activity in Individual Nerve Cells , 1956, Nature.

[29]  F. Gage,et al.  Spatial learning and memory following fimbria-fornix transection and grafting of fetal septal neurons to the hippocampus , 2004, Experimental Brain Research.

[30]  D. Selkoe,et al.  Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide , 1993, Cell.

[31]  G. Broze,et al.  Platelet coagulation factor XIa-inhibitor, a form of Alzheimer amyloid precursor protein. , 1990, Science.

[32]  M. Mattson,et al.  A model for beta-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[33]  D. Butterfield,et al.  Direct evidence of oxidative injury produced by the Alzheimer's β-Amyloid peptide (1–40) in cultured hippocampal neurons , 1995, Experimental Neurology.

[34]  M. Mattson,et al.  beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  L. Hunihan,et al.  Altered cleavage and secretion of a recombinant β–APP bearing the Swedish familial Alzheimer's disease mutation , 1994, Nature Genetics.

[36]  D. Selkoe,et al.  Mutation of the β-amyloid precursor protein in familial Alzheimer's disease increases β-protein production , 1992, Nature.

[37]  G. Huber,et al.  β‐Amyloid Precursor Protein Isoforms in Various Rat Brain Regions and During Brain Development , 1992 .

[38]  F M Miezin,et al.  Activation of the hippocampus in normal humans: a functional anatomical study of memory. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. C. Collins,et al.  Characterization of nicotine binding in mouse brain and comparison with the binding of alpha-bungarotoxin and quinuclidinyl benzilate. , 1982, Molecular pharmacology.

[40]  J. Gray,et al.  Effects of cholinergic-rich neural grafts on radial maze performance of rats after excitotoxic lesions of the forebrain cholinergic projection system—II. Cholinergic drugs as probes to investigate lesion-induced deficits and transplant-induced functional recovery , 1991, Neuroscience.

[41]  D. Price,et al.  Evidence that beta-amyloid protein in Alzheimer's disease is not derived by normal processing. , 1990, Science.

[42]  R. Lukas.  Effects of Chronic Nicotinic Ligand Exposure on Functional Activity of Nicotinic Acetylcholine Receptors Expressed by Cells of the PC12 Rat Pheochromocytoma or the TE671/RD Human Clonal Line , 1991, Journal of neurochemistry.

[43]  S. Younkin,et al.  Release of excess amyloid beta protein from a mutant amyloid beta protein precursor. , 1993, Science.

[44]  J L McGaugh,et al.  The role of interactions between the cholinergic system and other neuromodulatory systems in learing and memory , 1991, Synapse.

[45]  K. Blennow,et al.  Significance of decreased lumbar CSF levels of HVA and 5-HIAA in Alzheimer's disease , 1992, Neurobiology of Aging.

[46]  Walter Schubert,et al.  Localization of Alzheimer βA4 amyloid precursor protein at central and peripheral synaptic sites , 1991, Brain Research.

[47]  M. Pericak-Vance,et al.  Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[48]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[49]  T. Robbins,et al.  Dissociable effects on spatial maze and passive avoidance acquisition and retention following AMPA- and ibotenic acid-induced excitotoxic lesions of the basal forebrain in rats: Differential dependence on cholinergic neuronal loss , 1991, Neuroscience.

[50]  E. Jones,et al.  Neurotransmitters in the cerebral cortex. , 1986, Journal of neurosurgery.

[51]  S. Ball,et al.  Regulation of Noradrenaline Release from Rat Occipital Cortex Tissue Chops by α2‐Adrenergic Agonists , 1991, Journal of neurochemistry.

[52]  R. North,et al.  Acetylcholine acts on m2‐muscarinic receptors to excite rat locus coeruleus neurones , 1985, British journal of pharmacology.